Propranolol for Anxiety
Propranolol has limited evidence supporting its use for anxiety disorders and should not be routinely prescribed for this indication. The most recent and comprehensive systematic review from 2025 found no evidence of beneficial effect for propranolol compared to placebo or benzodiazepines in patients with social phobia or panic disorder 1.
Evidence Quality and Recommendations
The strongest guideline evidence addresses propranolol's use in specific psychiatric contexts, not generalized anxiety:
- Panic disorder: A 2022 guideline on hypertension comorbidities mentions propranolol for panic disorder when combined with cognitive behavioral therapy and/or SSRIs/benzodiazepines 2
- Social anxiety disorder: The 2023 Japanese clinical practice guideline for social anxiety disorder does not recommend propranolol at all. Instead, it recommends SSRIs/SNRIs as first-line pharmacotherapy and cognitive behavioral therapy as first-line psychotherapy 3
Meta-Analysis Findings
Two systematic reviews provide the highest quality evidence:
- 2025 meta-analysis (n=179): No beneficial effect versus placebo or benzodiazepines for social phobia or panic disorder (p≥0.54 for all comparisons) 1
- 2016 meta-analysis: No statistically significant differences between propranolol and benzodiazepines for panic disorder; insufficient evidence to support routine use in any anxiety disorder 4
When Propranolol May Be Considered
Performance anxiety/stage fright is the primary evidence-based indication, though this is off-label in most countries 2, 5:
- Dosing: 20-40 mg orally, taken 1-2 hours before the performance
- Mechanism: Blocks peripheral beta-adrenergic receptors, reducing somatic symptoms (tremor, palpitations, sweating)
- Onset: 1-2 hours 6
The 20 mg dose provides significant anxiety reduction with minimal side effects compared to 40 mg (which showed 25% bradycardia and 10% hypotension rates) 7.
Dosing Regimens (When Used)
Based on FDA labeling and older research 8, 9:
- Acute/performance anxiety: 20-40 mg single dose, 1-2 hours before event
- Chronic anxiety (historical use, not evidence-based): 80-320 mg daily in divided doses, though doses up to 1200 mg were reported in older uncontrolled studies
Critical Limitations and Contraindications
Absolute contraindications:
- Second or third-degree heart block
- Decompensated heart failure
- Severe reactive airway disease/asthma
- Hypotension
- Bradycardia
Common pitfalls:
- Propranolol is increasingly prescribed for anxiety despite lack of robust evidence 1
- Many studies have small sample sizes, high risk of bias, and missing data 1, 4
- The drug primarily addresses somatic symptoms (tremor, palpitations), not cognitive/psychological anxiety symptoms 6
Evidence-Based Alternatives
For generalized anxiety and social anxiety disorder, SSRIs remain first-line pharmacotherapy 3. For panic disorder, benzodiazepines showed equivalent efficacy to propranolol in limited trials 4.
Bottom line: While propranolol may help with acute performance anxiety by reducing peripheral somatic symptoms, there is insufficient evidence to support its routine use for anxiety disorders. The 2025 systematic review explicitly calls for a large RCT to provide definitive evidence, acknowledging the current evidence base is inadequate despite increasing prescribing patterns 1.